Financial risk of the Biotech Industry versus the Pharmaceutical Industry

被引：0

作者：

Joseph Golec

John A. Vernon

机构：

[1] University of Connecticut,Finance Department, School of Business

[2] University of North Carolina,Department of Health Policy and Administration

[3] National Bureau of Economic Research,undefined

来源：

Applied Health Economics and Health Policy | 2009年 / 7卷 / 3期

关键词：

Stock Market; Stock Return; Systematic Risk; Financial Risk; Pharmaceutical Firm;

D O I：

10.1007/BF03256149

中图分类号：

学科分类号：

摘要：

The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical industries in the US and the implications of this fragility for the effects that government regulation could have on biotech firms.

引用

页码：155 / 165

页数：10

共 50 条

[11] A FINANCIAL PERSPECTIVE ON THE PHARMACEUTICAL INDUSTRY
Kahraman, Yunus Emre
Caliskan, Yilmaz
PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, (01): : 23 - 31
[12] Pharmaceutical industry financial performance
Goodman, Michael
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (12) : 927 - 928
[13] Pharmaceutical industry financial performance
Michael Goodman
Nature Reviews Drug Discovery, 2009, 8 : 927 - 928
[14] Front-end engineering for pharmaceutical & biotech industry
Reifferscheid, M
CHIMIA, 2003, 57 (1-2) : 55 - 55
[15] INDUSTRY FINANCE - BIOTECH SAILS INTO HEAVY FINANCIAL SEAS
STONE, R
SCIENCE, 1993, 260 (5110) : 908 - 910
[16] Risk assessment in the pharmaceutical industry
Prout, G
34TH R3-NORDIC CONTAMINATION CONTROL SYMPOSIUM, 2003, 229 : 239 - 243
[17] Market differential evaluations of strategic alliances in the pharmaceutical/biotech industry
Faculty of Business and Economics, Wilfrid Laurier University, Waterloo, Ont. N2L 3C5, Canada
J. High Technol. Manage. Res., 2006, 1 (43-52):
[18] BMGT 5 - Globalization and its implications and opportunities for the biotech and pharmaceutical industry: Is it time for the pharmaceutical industry to reevaluate its approach?
Chaturvedi, Pravin
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238 : 934 - 934
[19] Financial Situation of Listed Companies in Pharmaceutical Industry
Yan, Haokun
Xu, Ting
PROCEEDINGS OF THE FIFTH SYMPOSIUM OF RISK ANALYSIS AND RISK MANAGEMENT IN WESTERN CHINA (WRARM 2017), 2017, 152 : 110 - 114
[20] Spain breaks financial pact with pharmaceutical industry
Xavier Bosch
Nature Medicine, 2004, 10 : 1145 - 1145

← 1 2 3 4 5 →